Pfizer
PFE
$25.96
+0.35%
Pfizer Inc. is a global pharmaceutical giant operating in the Drug Manufacturers - General industry, with a core business focused on developing, manufacturing, and commercializing prescription drugs and vaccines. The company is a market leader, distinguished by its massive scale, extensive R&D pipeline, and a portfolio of blockbuster products like Prevnar 13, Eliquis, and Vyndaqel. The current investor narrative is dominated by the company's post-pandemic transition, as it navigates the steep decline in COVID-19 product revenue while attempting to rebuild growth through its oncology pipeline, as evidenced by recent positive late-stage trial results for cancer therapies like ELREXFIO and Talzenna/Xtandi, and strategic moves in a challenging regulatory environment marked by potential drug tariffs.…
PFE
Pfizer
$25.96
Related headlines
Investment Opinion: Should I buy PFE Today?
Rating: Hold. The core thesis is that Pfizer is a deeply valued, cash-generative pharmaceutical giant in a difficult transition, where promising pipeline catalysts are currently outweighed by severe near-term earnings volatility and negative momentum.
Supporting evidence includes a forward P/E of 11.8x based on analyst EPS estimates of $2.24, which is below the sector average for large-cap pharma, suggesting the market is not pricing in a recovery. The trailing PS ratio of 2.26 represents a steep discount to the stock's own historical multiples above 15.9. Furthermore, the robust TTM free cash flow of $9.08 billion supports the high 6.9% dividend yield, and analyst consensus sentiment leans cautiously optimistic with an upgrade from Argus Research noted.
The thesis would upgrade to a Buy if the forward P/E compresses below 10x on sustained positive pipeline news, or if quarterly revenue returns to consistent YoY growth above 2%. It would downgrade to a Sell if the dividend payout ratio (currently 125%) becomes unsustainable due to prolonged earnings weakness, or if the stock breaks below its 52-week low of $21.97 on failed catalysts. Relative to its history and the sector, the stock is undervalued, but it is fairly valued given the significant execution risks and lack of near-term earnings visibility.
Sign up to view all
PFE 12-Month Price Forecast
The outlook for Pfizer is one of high uncertainty balanced by compelling value. The base case (60% probability) of a range-bound stock is most likely, as the company works through its post-COVID transition. The robust cash flow and high dividend yield provide a floor, while the promising but unproven oncology pipeline offers optionality for upside. The stance would upgrade to bullish on evidence of sustainable quarterly revenue growth and margin expansion. It would turn bearish if the dividend safety comes into question or the stock breaks key technical support at $21.97.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $33.75 and implied upside of +30.0% versus the current price.
Average Target
$33.75
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$21 - $34
Analyst target range
Analyst coverage for Pfizer is substantial, with 11 analysts providing estimates, and recent institutional ratings show a mix of Buy and Neutral stances, including an upgrade from Argus Research from Hold to Buy in March 2026. The consensus sentiment leans cautiously optimistic, with an average EPS estimate of $2.24 for the upcoming period, implying a forward P/E of approximately 11.8x based on the current price, which is below the trailing P/E of 18.2, signaling expectations for earnings recovery. The target price range derived from revenue estimates suggests a high degree of uncertainty regarding future performance; the high revenue estimate of $52.89 billion assumes successful pipeline execution and commercial recovery, while the low estimate of $50.05 billion reflects more conservative growth assumptions, with the wide $2.84 billion spread between high and low estimates underscoring the lack of clarity on Pfizer's near-term growth trajectory post its COVID winddown.
Bulls vs Bears: PFE Investment Factors
The investment debate for Pfizer centers on a clash between deep-value fundamentals and deteriorating near-term operational momentum. The bear case currently holds stronger evidence, as reflected in the stock's persistent downtrend, severe quarterly earnings volatility, and ongoing revenue declines. However, the bull case is supported by a historically cheap valuation, a fortress balance sheet with strong cash flow, and promising pipeline catalysts. The single most important tension is whether the promising oncology pipeline (ELREXFIO, Talzenna/Xtandi) can deliver commercial success quickly and significantly enough to offset the steep COVID-related revenue cliff and restore consistent earnings growth before investor patience wears thin.
Bullish
- Deep Valuation Discount: The stock trades at a trailing PS ratio of 2.26, a fraction of its historical highs above 15.9. This significant discount to its own history suggests the market has priced in extreme pessimism, creating a potential value opportunity if the core business stabilizes.
- Strong Cash Generation: Despite earnings volatility, Pfizer generated $9.08 billion in TTM free cash flow and $5.35 billion in Q4 operating cash flow. This robust cash generation funds the 6.9% dividend yield, R&D, and business development, providing a defensive financial floor.
- Oncology Pipeline Success: Recent positive late-stage trial results for cancer therapies like ELREXFIO and Talzenna/Xtandi provide a clear path to future growth. These catalysts are critical for rebuilding the revenue base as COVID-related sales decline.
- Analyst Earnings Recovery Expected: Analysts forecast forward EPS of $2.24, implying a forward P/E of approximately 11.8x, which is below the trailing P/E of 18.2x. This expectation for earnings normalization is a key pillar for a potential re-rating.
Bearish
- Severe Earnings Volatility: Q4 2025 saw a net loss of -$1.65 billion and EPS of -$0.29, a stark reversal from Q3's profit of $3.54 billion. This extreme quarterly inconsistency undermines earnings visibility and investor confidence in near-term forecasts.
- Persistent Revenue Decline: Q4 2025 revenue of $17.56 billion declined 1.16% YoY, continuing the post-COVID revenue headwind. The wide $2.84 billion spread between high and low analyst revenue estimates underscores the uncertainty surrounding the top-line trajectory.
- Gross Margin Pressure: Gross margin compressed to 69.97% in Q4 from 74.95% in Q3, indicating product mix deterioration and potential pricing pressures. Sustained margin erosion would threaten the company's profitability and cash flow generation.
- Technical Downtrend & Underperformance: The stock is down 7.78% over one month and trades near the midpoint of its 52-week range, showing weak momentum. It has underperformed the SPY by -17.76% over the same period, reflecting significant negative sentiment and capital outflow.
PFE Technical Analysis
The stock is in a sustained downtrend over the short term, with a 1-month price change of -7.78%, contrasting a modest 1-year gain of 10.03%. The current price of $26.33 sits approximately 51% of its 52-week range ($21.97 to $28.75), indicating it is trading much closer to its annual lows than its highs, which may signal a potential value opportunity but also reflects significant negative momentum and investor pessimism. Recent momentum has been sharply negative, with the 1-month decline of -7.78% and a 3-month drop of -0.42%, diverging significantly from the positive 1-year trend and suggesting a strong bearish reversal or capitulation phase, a view reinforced by the stock's severe underperformance relative to the SPY, with a relative strength of -17.76% over one month. Key technical support is clearly defined at the 52-week low of $21.97, while resistance lies at the 52-week high of $28.75; a breakdown below $21.97 would signal a new leg down, while a sustained move above $28.75 would be needed to invalidate the downtrend. The stock's beta of 0.388 indicates it is approximately 61% less volatile than the broader market, which historically provided defensive characteristics but has not shielded it from recent aggressive selling pressure.
Beta
0.30
0.30x market volatility
Max Drawdown
-11.5%
Largest decline past year
52-Week Range
$22-$29
Price range past year
Annual Return
+13.5%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | -5.0% | +8.2% |
| 3m | -5.5% | +9.0% |
| 6m | +3.6% | +10.5% |
| 1y | +13.5% | +26.5% |
| ytd | +3.1% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Revenue growth is currently negative and volatile, with the most recent Q4 2025 revenue of $17.56 billion representing a year-over-year decline of 1.16%, following a pattern of uneven quarterly results that includes a strong Q3 2025 revenue of $16.65 billion with positive year-over-year comparisons, indicating the core business is stabilizing but facing significant headwinds from the loss of COVID-related sales. Profitability is highly inconsistent, as evidenced by a Q4 2025 net income loss of -$1.65 billion and an EPS of -$0.29, which contrasts sharply with a profitable Q3 2025 showing net income of $3.54 billion and EPS of $0.62; however, the company maintains robust underlying gross margins of 69.97% in Q4, though this is down from the 74.95% reported in Q3, pointing to potential product mix shifts and pricing pressures. The balance sheet and cash flow position remains a relative strength, with a manageable debt-to-equity ratio of 0.78, strong trailing twelve-month free cash flow of $9.08 billion, and a current ratio of 1.16, indicating the company generates substantial cash to fund its operations, dividends, and business development despite earnings volatility, though the Q4 2025 operating cash flow of $5.35 billion was impacted by a significant working capital build.
Quarterly Revenue
$17.6B
2025-12
Revenue YoY Growth
-0.01%
YoY Comparison
Gross Margin
+0.69%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Given the company reported negative net income in the most recent quarter, we lead with the Price-to-Sales (PS) ratio for valuation. The trailing PS ratio is 2.26, while the forward PS, implied by the market cap and analyst revenue estimates, is approximately 2.74, suggesting the market expects modest top-line growth. Compared to sector averages, a PS of 2.26 is generally at a discount to many larger, growth-oriented biopharma peers, though a direct industry average PS is not provided in the data; the discount likely reflects concerns over growth sustainability and earnings volatility post-COVID. Historically, the current PS of 2.26 is near the lower end of its own historical range observed in the provided data, which has seen PS ratios fluctuate from approximately 8.46 in late 2024 to over 15.9 in mid-2022, indicating the stock is being valued at a significant discount to its recent past, which may price in a more pessimistic long-term growth outlook or present a value opportunity if the pipeline delivers.
PE
18.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -21x~1666x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, centered on extreme earnings volatility and margin pressure. The Q4 2025 net loss of -$1.65 billion versus a Q3 profit of $3.54 billion demonstrates a lack of earnings stability, making forecasting difficult. While annual free cash flow of $9.08 billion is strong, the recent gross margin decline from 74.95% to 69.97% quarter-over-quarter signals underlying profitability challenges. Revenue concentration risk is evolving, as the company transitions away from COVID products, creating a growth gap that new launches must fill rapidly.
Market & Competitive Risks include valuation compression and sector-specific regulatory threats. Although the current PS ratio of 2.26 appears discounted historically, it could compress further if growth fails to materialize. The stock's low beta of 0.388 has not prevented severe underperformance (-17.76% vs. SPY over 1 month), indicating company-specific issues outweigh defensive characteristics. Recent news of potential 100% drug tariffs introduces a new regulatory overhang, creating a bifurcated market where Pfizer's competitive position could be challenged depending on its pricing agreements.
Worst-Case Scenario involves a failure of the key oncology pipeline catalysts combined with accelerated gross margin erosion and a dividend cut. In this adverse scenario, revenue estimates could trend toward the analyst low of $50.05 billion, and the stock could re-test its 52-week low of $21.97. From the current price of $26.33, this represents a realistic downside of approximately -17%. A more severe bear case, factoring in a loss of investor confidence in the turnaround narrative, could see the stock fall toward the $20 level, implying a potential loss of -24% or more.
FAQ
The key risks are, in order of severity: 1) Earnings & Revenue Risk: Extreme quarterly volatility, as seen in the swing from a $3.54B profit in Q3 to a -$1.65B loss in Q4, coupled with persistent revenue declines. 2) Pipeline Execution Risk: The company's future growth is heavily reliant on successful launches of oncology drugs like ELREXFIO; any delay or commercial disappointment would extend the growth gap. 3) Dividend Sustainability Risk: The payout ratio of 125.7% is unsustainably high if earnings do not recover promptly. 4) Regulatory & Macro Risk: Potential new drug tariffs and a challenging pricing environment add external pressure.
The 12-month forecast is characterized by three scenarios. The base case (60% probability) sees the stock trading between $26 and $30, as the company muddles through its transition with volatile earnings meeting analyst estimates near $2.24 EPS. The bull case (25% probability) targets $31 to $35 on successful pipeline launches and a valuation re-rating. The bear case (15% probability) risks a drop to the $21 to $25 range, testing the 52-week low, on pipeline disappointments and worsening fundamentals. The base case is most likely, hinging on the assumption that analyst EPS forecasts are achievable.
PFE is undervalued relative to its own history but may be fairly valued given current risks. The trailing Price-to-Sales ratio of 2.26 is a fraction of its mid-2022 level above 15.9, indicating a deep historical discount. The forward P/E of 11.8x is below the trailing P/E of 18.2x and is generally at a discount to many growth-oriented pharma peers. This valuation implies the market expects only a modest earnings recovery and has significant doubts about the company's growth trajectory post-COVID. The discount is justified by the operational uncertainty but creates a potential opportunity if execution improves.
PFE presents a complex risk/reward profile. For value and income investors, it offers a compelling 6.9% dividend yield supported by strong underlying cash flow, and trades at a significant discount to its historical valuation with a forward P/E of 11.8x. However, it is not a good buy for growth-oriented investors or those with low risk tolerance, given the severe quarterly earnings volatility, ongoing revenue headwinds, and negative price momentum. A purchase should be predicated on a belief in the long-term success of its oncology pipeline and a willingness to hold through potential further volatility.
PFE is unsuitable for short-term trading due to its low beta (0.388) limiting trading volatility, negative momentum, and high dependence on long-term pipeline developments. It is primarily a long-term investment for income-focused portfolios. The high dividend yield and deep value characteristics require a multi-year horizon to allow the company's strategic transition to play out. Investors should be prepared to hold for a minimum of 3-5 years to potentially realize the value embedded in the pipeline and await a possible earnings and multiple recovery.